Biolab strengthens action against Central Nervous System diseases

In Brazil, more than 30 million people suffer from mental disorders, according to the study Depression and Other Common Mental Disorders (Geneva - 2017) carried out by the World Health Organization (WHO). This impressive figure leads Biolab Farmacêutica, an established company and leader in different specialties, to invest more and more in its portfolio for diseases of the Central Nervous System (CNS), helping to improve patients' quality of life.

"Doctors and patients recognize the quality of our medicines. We are taking this relationship of trust to CNS diseases. We are putting our expertise, structure and team of professionals to work in this therapeutic class of growing importance to the Brazilian population," says Dr. Dante Alario Jr., CSO of Biolab Sanus Farmacêutica.

The CNS is responsible for receiving and interpreting the most diverse messages coming from the various parts of the body. Irregular functioning of the nervous system is linked to numerous illnesses such as depression, panic disorder, generalized anxiety disorder (GAD), social anxiety disorder (social phobia), obsessive compulsive disorder (OCD) and others.

"Several issues are linked to patients with mental disorders, such as psychophobia, prejudice and awareness. Biolab acts responsibly and comprehensively on these problems; not only with its medicines, but also with support for organizations linked to the issue," says Biolab's CSO.

With over 20 years of history, Biolab Farmacêutica stands out for its innovative profile. The company has four industrial plants and two research, development and innovation centers, one in Brazil and the other in Canada.